Prescribing information

 

________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________

Unravel the science of the damage caused by SCD

The driving mechanism that causes complications in patients with SCD goes beyond red blood cells (RBCs)and includes anaemia, vaso‑occlusive crises (VOCs), fatigue and infections.1–7 Vaso‑occlusion is largely driven by multicellular adhesion, which itself is a result of the chronic inflammatory state of the blood vessels of people with SCD8

For more information and support on treating your patients with SCD you may like to visit:

National Haemoglobinopathy Panel (NHP)

Provide ‘on request’ expert and evidence‑based advice to clinicians on the management of adults and children with SCD, thalassaemia and rare inherited anaemias in the UK

The Sickle Cell Society (SCS)

Support and represent people affected by SCD to improve their overall quality of life. They have a number of planned activities throughout the year and online resources available for patients to learn more about their condition and provide support

 

Abbreviations: NHP, National Haemoglobinopathy Panel; RBC, red blood cell; SCD, sickle cell disease; SCS, The Sickle Cell Society; VOCs, vaso-occlusive crises.

References

  1. Zhang D, et al. Blood. 2016;127(7):801–809.
  2. Shah N, et al. PLoS ONE. 2019;14(7):e0214355.
  3. Ballas SK, et al. Blood. 2012;120(18):3647–3656.
  4. Puri L, et al. Paediatr Drugs. 2018;20(1):29–42.
  5. Ameringer S, et al. J Pediatr Oncol Nurs. 2014;31(1):6–17.
  6. Booth C, et al. Int J Infect Dis. 2010;14(1):e2–e12.
  7. Piel FB, et al. N Engl J Med. 2017;376(16):1561–1573.
  8. Conran N, et al. Hemoglobin. 2009;33(1):1–16.
Rate this content: 
No votes yet
UK | April 2021 | 104279

For more information, refer to the ADAKVEO® (crizanlizumab) prescribing information available here: www.health.novartis.co.uk/sites/health.novartis.co.uk/files/adakveo-pi.pdf

Legal Category: POM.

Marketing Authorisation (MA) number, quantities and price: EU/1/20/1476/001  £1,038.00 per 10ml vial

 

×

Ask Speakers

×

Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at www.report.novartis.com
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]